Newsfeed | Navigating EGFR

Increased reporting of interstitial pneumonitis with combined EGFR-TKI and PD-1/PD-L1 inhibitor therapy in NSCLC: a pharmacovigilance analysis of 67,818 reports

Read more about Increased reporting of interstitial pneumonitis with combined EGFR-TKI and PD-1/PD-L1 inhibitor therapy in NSCLC: a pharmacovigilance analysis of 67,818 reports

ImportanceBoth epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and PD-1/PD-L1 inhibitors are widely used in non–small cell lung cance Abstract Importance: Both epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and PD-1/PD-L1 inhibitors are widely used in non–small cell...

Three-year adjuvant treatment of icotinib in stage II-IIIA EGFR-mutated lung adenocarcinoma (ICWIP): a randomized, double-blind, placebo-controlled phase 3 trial

Read more about Three-year adjuvant treatment of icotinib in stage II-IIIA EGFR-mutated lung adenocarcinoma (ICWIP): a randomized, double-blind, placebo-controlled phase 3 trial

This multi-center, double-blind, placebo-controlled, randomized phase 3 trial (ICWIP) assessed the efficacy and safety of 3-year icotinib adjuvant treatment versus placebo in patients with completely resected stage II-IIIA epidermal growth factor receptor (EGFR) mutated lung adenocarcinoma who had completed four...

Low baseline HbA1c and reduced eGFR are associated with relatively unfavorable body recomposition after SGLT2 inhibitor therapy in type 2 diabetes

Read more about Low baseline HbA1c and reduced eGFR are associated with relatively unfavorable body recomposition after SGLT2 inhibitor therapy in type 2 diabetes

AimsSodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve glycemic control and promote weight l https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000…, identifier UMIN000048469; https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000…, identifier UMIN000048471. Abstract Aims: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve glycemic control...

Case Report: Targeting EGFR exon 20 insertion and MTAP loss in refractory metastatic upper tract urothelial carcinoma

Read more about Case Report: Targeting EGFR exon 20 insertion and MTAP loss in refractory metastatic upper tract urothelial carcinoma

Abstract This case report illustrates the use of amivantamab in combination with pemetrexed-based chemotherapy for the treatment of a 60-year-old man with refractory metastatic upper tract urothelial carcinoma (UTUC) with epidermal growth factor receptor (EGFR) exon 20 insertion (D770_N771insGF) and...

Genfleet Therapeutics-B (02595): GFH375 (an oral KRAS G12D inhibitor) has entered a Phase II study for first-line treatment of non-small cell lung cancer, exploring multiple therapeutic regimens including monotherapy, combination with EGFR monoclonal anti

Read more about Genfleet Therapeutics-B (02595): GFH375 (an oral KRAS G12D inhibitor) has entered a Phase II study for first-line treatment of non-small cell lung cancer, exploring multiple therapeutic regimens including monotherapy, combination with EGFR monoclonal anti

Jinfang Medicine-B (02595) announced that GFH375 has entered a Phase II study for first-line treatment of advanced non-small cell lung cancer (NSCLC) with KRAS G12D mutations. The study includes three treatment regimens: monotherapy, combination with an EGFR monoclonal antibody (cetuximab),...

Identification of EGFR, MMP9, and AGTR1 as actionable therapeutic targets in acetyl tributyl citrate-driven breast cancer: integrated network toxicology and in vitro validation

Read more about Identification of EGFR, MMP9, and AGTR1 as actionable therapeutic targets in acetyl tributyl citrate-driven breast cancer: integrated network toxicology and in vitro validation

BackgroundGrowing exposure to acetyl tributyl citrate (ATBC) drives breast cancer (BC) progression and poses significant challenges to clinical management. H Abstract Background: Growing exposure to acetyl tributyl citrate (ATBC) drives breast cancer (BC) progression and poses significant challenges to clinical...

Cooperation of luteinizing hormone and estradiol in the promotion of goat oocyte maturation via regulation and activation of the GPR30 and EGFR signaling pathways

Read more about Cooperation of luteinizing hormone and estradiol in the promotion of goat oocyte maturation via regulation and activation of the GPR30 and EGFR signaling pathways

Abstract The luteinizing hormone (LH) is well established to trigger oocyte maturation and cumulus expansion in preovulatory follicles, primarily through activating the epidermal growth factor (EGF) signaling network. While previous studies have demonstrated that activation of the G protein-coupled estrogen...

Subscribe to Newsfeed